<DOC>
	<DOCNO>NCT00093808</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine vinorelbine , work different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor kill substance without harm normal cell . Giving capecitabine vinorelbine together trastuzumab may kill tumor cell . PURPOSE : This phase II trial study well give capecitabine vinorelbine together trastuzumab work treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Capecitabine , Vinorelbine , Trastuzumab Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall response rate patient HER2/neu-overexpressing metastatic breast cancer treat first- second-line therapy comprise capecitabine , vinorelbine , trastuzumab ( Herceptin^® ) . Secondary - Determine time disease progression , duration response , overall survival patient treat regimen . - Determine safety profile regimen patient . OUTLINE : This multicenter study . Patients receive oral capecitabine twice daily day 1-14 , vinorelbine IV 6-10 minute day 1 8 , trastuzumab ( Herceptin^® ) IV 30-90 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month disease progression every 6 month 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm invasive breast cancer Metastatic disease HER2/neupositive immunohistochemistry ( 3+ HercepTest^™ equivalent ) OR positive amplification fluorescent situ hybridization Testing may perform primary tumor metastatic site Received prior anthracycline taxane adjuvant therapy metastatic disease Measurable disease At least one measurable lesion ≥ 2.0 cm CT scan MRI OR ≥ 1.0 cm spiral CT scan The following consider nonmeasurable disease : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion No bone metastases evidence metastasis Previously treat CNS metastasis allow provided disease stable ≥ past 3 month Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female male Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 100,000/mm^3 No known uncontrolled coagulopathy Hepatic Bilirubin ≤ 3.0 time upper limit normal ( ULN ) One follow must true : AST ALT ≤ 5 time ULN AND alkaline phosphatase normal Alkaline phosphatase ≤ 5 time ULN AND AST ALT normal Alkaline phosphatase ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN INR ≤ 1.5 time ULN Renal Calcium ≤ 11.5 mg/dL Creatinine ≤ 1.5 time ULN Creatinine clearance ≥ 30 mL/min Cardiovascular LVEF ≥ 50 % MUGA echocardiogram No clinically significant ( i.e. , active ) cardiac disease No congestive heart failure No symptomatic coronary artery disease No myocardial infarction within past 12 month No cardiac arrhythmia control medication Gastrointestinal Able take oral medication No lack physical integrity upper gastrointestinal tract No clinically significant malabsorption syndrome Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day study participation No history allergy hypersensitivity study drug , drug product excipients , include polysorbate 80 , chemically similar agent No prior unanticipated severe reaction fluoropyrimidine therapy No know hypersensitivity fluorouracil No known dihydropyrimidine dehydrogenase deficiency No history uncontrolled seizure CNS disorder No clinically significant psychiatric disability would preclude give informed consent study compliance No serious uncontrolled infection disease No malignancy within past 5 year except cure basal cell skin cancer , carcinoma situ cervix , contralateral breast cancer PRIOR CONCURRENT THERAPY : Biologic therapy Prior adjuvant trastuzumab ( Herceptin^® ) allow adjuvant firstline therapy metastatic disease No concurrent immunotherapy Chemotherapy See Disease Characteristics No 1 prior chemotherapy regimen advance metastatic ( nonadjuvant ) set No prior continuous ( ≥ 24 hour ) fluorouracil infusion No prior capecitabine No prior oral fluoropyrimidines ( e.g. , eniluracil fluorouracil , uracil tegafur , S1 , emitefur ) Endocrine therapy At least 1 day since prior hormonal therapy No concurrent hormonal therapy Radiotherapy More 4 week since prior radiotherapy axial skeleton ( i.e. , skull , spinal column , sternum , rib ) No concurrent radiotherapy Surgery More 4 week since prior major surgery No prior organ allograft require immunosuppressive therapy Other More 4 week since prior investigational drug No concurrent sorivudine chemically related analogue ( e.g. , brivudine ) No concurrent allopurinol , metronidazole , cimetidine No concurrent cytotoxic agents No concurrent investigational drug No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>